financetom
Business
financetom
/
Business
/
Dolby Laboratories Fiscal Q1 Non-GAAP EPS, Revenue Increase; Issues Q2, Full-Year Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dolby Laboratories Fiscal Q1 Non-GAAP EPS, Revenue Increase; Issues Q2, Full-Year Outlook
Jan 29, 2025 2:30 PM

05:09 PM EST, 01/29/2025 (MT Newswires) -- Dolby Laboratories ( DLB ) reported fiscal Q1 non-GAAP earnings Wednesday of $1.14 per diluted share, up from $1.01 a year earlier.

Three analysts polled by FactSet expected $1.05.

Revenue for the quarter ended Dec. 27 was $357 million, up from $315.6 million a year earlier.

Three analysts surveyed by FactSet expected $346.1 million.

The company said it expects Q2 non-GAAP diluted EPS between $1.19 and $1.34 and revenue between $355 million and $385 million.

Three analysts polled by FactSet expect $1.35 and $387.2 million.

The company expects fiscal 2025 non-GAAP diluted EPS between $3.99 and $4.14 and revenue between $1.33 billion and $1.39 billion.

Three analysts surveyed by FactSet expect revenue of $1.36 billion.

The company's shares were falling 1.1% in recent after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CAE Signs Global Cooperation Agreement With Saab for GlobalEye Training Platforms
CAE Signs Global Cooperation Agreement With Saab for GlobalEye Training Platforms
Nov 20, 2025
04:01 PM EST, 11/20/2025 (MT Newswires) -- CAE (CAE.TO, CAE) said Thursday it signed a worldwide cooperation agreement making the company Saab's preferred supplier for select training and simulation requirements tied to its GlobalEye Airborne Early Warning and Control (AEW&C) aircraft and other platforms. The deal also includes a Canada-specific agreement to jointly pursue the country's AEW&C program. CAE Chief...
Revolution Medicines Insider Sold Shares Worth $939,008, According to a Recent SEC Filing
Revolution Medicines Insider Sold Shares Worth $939,008, According to a Recent SEC Filing
Nov 20, 2025
04:29 PM EST, 11/20/2025 (MT Newswires) -- Jeff Cislini, General Counsel, on November 18, 2025, sold 13,388 shares in Revolution Medicines ( RVMD ) for $939,008. Following the Form 4 filing with the SEC, Cislini has control over a total of 50,425 common shares of the company, with 50,425 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1628171/000161071725000383/xslF345X05/form4.xml ...
Atlassian Insider Sold Shares Worth $444,896, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $444,896, According to a Recent SEC Filing
Nov 20, 2025
04:30 PM EST, 11/20/2025 (MT Newswires) -- Rajeev Bashyam Rajan, Chief Technology Officer, on November 19, 2025, sold 3,017 shares in Atlassian ( TEAM ) for $444,896. Following the Form 4 filing with the SEC, Rajan has control over a total of 219,997 Class A common shares of the company, with 219,997 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000194361425000004/xslF345X05/primarydocument.xml ...
Revolution Medicines Insider Sold Shares Worth $1,407,586, According to a Recent SEC Filing
Revolution Medicines Insider Sold Shares Worth $1,407,586, According to a Recent SEC Filing
Nov 20, 2025
04:29 PM EST, 11/20/2025 (MT Newswires) -- Mark A Goldsmith, Director, President and Chief Executive Officer, on November 18, 2025, sold 20,000 shares in Revolution Medicines ( RVMD ) for $1,407,586. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 958,761 common shares of the company, with 247,863 shares held directly and 710,898 controlled...
Copyright 2023-2026 - www.financetom.com All Rights Reserved